Abeona Therapeutics (NASDAQ:ABEO) Lifted to “Sell” at BidaskClub

BidaskClub upgraded shares of Abeona Therapeutics (NASDAQ:ABEO) from a strong sell rating to a sell rating in a report issued on Tuesday, BidAskClub reports.

Other research analysts also recently issued research reports about the company. HC Wainwright set a $23.00 target price on Abeona Therapeutics and gave the stock a buy rating in a research note on Tuesday, May 28th. Cantor Fitzgerald reissued a buy rating and set a $29.00 target price on shares of Abeona Therapeutics in a research note on Tuesday, May 14th. Maxim Group reissued a buy rating on shares of Abeona Therapeutics in a research note on Wednesday, May 1st. ValuEngine raised Abeona Therapeutics from a sell rating to a hold rating in a research note on Tuesday, March 5th. Finally, Zacks Investment Research raised Abeona Therapeutics from a sell rating to a hold rating in a research note on Wednesday, March 20th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and six have given a buy rating to the company’s stock. The stock currently has an average rating of Buy and an average price target of $24.83.

ABEO stock opened at $5.26 on Tuesday. The stock has a market capitalization of $258.59 million, a P/E ratio of -4.42 and a beta of 2.13. Abeona Therapeutics has a 52 week low of $5.02 and a 52 week high of $17.25. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.35 and a quick ratio of 3.35.



Abeona Therapeutics (NASDAQ:ABEO) last posted its quarterly earnings results on Monday, March 18th. The biopharmaceutical company reported ($0.36) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.42) by $0.06. The business had revenue of $0.50 million during the quarter, compared to the consensus estimate of $1.66 million. Abeona Therapeutics had a negative return on equity of 45.58% and a negative net margin of 960.91%. On average, sell-side analysts predict that Abeona Therapeutics will post -1.6 earnings per share for the current fiscal year.

In other Abeona Therapeutics news, Director Stephen B. Howell bought 4,000 shares of the stock in a transaction on Monday, April 8th. The stock was purchased at an average price of $7.77 per share, with a total value of $31,080.00. Following the completion of the purchase, the director now owns 6,000 shares in the company, valued at $46,620. The purchase was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Stefano Buono bought 70,000 shares of the stock in a transaction on Thursday, April 11th. The shares were acquired at an average cost of $7.80 per share, with a total value of $546,000.00. Following the purchase, the director now owns 20,980 shares of the company’s stock, valued at approximately $163,644. The disclosure for this purchase can be found here. 33.60% of the stock is currently owned by insiders.

Institutional investors have recently added to or reduced their stakes in the company. SG Americas Securities LLC increased its stake in shares of Abeona Therapeutics by 23.7% in the fourth quarter. SG Americas Securities LLC now owns 22,720 shares of the biopharmaceutical company’s stock valued at $162,000 after buying an additional 4,351 shares during the period. Geode Capital Management LLC increased its stake in shares of Abeona Therapeutics by 2.0% in the fourth quarter. Geode Capital Management LLC now owns 341,206 shares of the biopharmaceutical company’s stock valued at $2,436,000 after buying an additional 6,826 shares during the period. Barclays PLC increased its stake in shares of Abeona Therapeutics by 184.9% in the fourth quarter. Barclays PLC now owns 62,885 shares of the biopharmaceutical company’s stock valued at $450,000 after buying an additional 40,811 shares during the period. Fosun International Ltd increased its stake in shares of Abeona Therapeutics by 37.6% in the first quarter. Fosun International Ltd now owns 98,900 shares of the biopharmaceutical company’s stock valued at $719,000 after buying an additional 27,000 shares during the period. Finally, Alps Advisors Inc. acquired a new position in shares of Abeona Therapeutics in the fourth quarter valued at approximately $791,000. 63.61% of the stock is owned by institutional investors.

About Abeona Therapeutics

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.

Further Reading: What are the benefits of a balanced fund?

Analyst Recommendations for Abeona Therapeutics (NASDAQ:ABEO)

Receive News & Ratings for Abeona Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.